The Medicine Maker

@medicine_maker

Exploring the human side of drug manufacturing & development. 💊Editor: . 💊Deputy Editor:

Knutsford, UK / New York City, NY
Vrijeme pridruživanja: svibanj 2014.

Tweetovi

Blokirali ste korisnika/cu @medicine_maker

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @medicine_maker

  1. Prikvačeni tweet

    Do you want to share the story behind your technology in a future issue of The Medicine Maker? In our December 2019 issue, The Medicine Maker will showcase the top 15 technologies released throughout 2019! Nominate now with the link below 👇

    Poništi
  2. As the world's largest supplier of heparin, China's ongoing African swine fever outbreak is a cause of concern, particularly for the US who rely on the porcine-derived product an anticoagulant.

    Poništi
  3. China has one of the world's largest supply of pigs. As African swine fever causes the decline of the country's stock, fear is building about the future of porcine-derived heparin.

    Poništi
  4. 4. velj

    Chinks in the pharmaceutical industry’s armor have allowed fake and counterfeit drugs to becoming a significant problem. Here, we speak to Bright Simons, President , to find out how digital technologies are helping to address the problem.

    Poništi
  5. 4. velj

    John Fowler, COO at Piramal Pharma Solutions, discusses the challenges CDMOs face in manufacturing these drugs.

    Poništi
  6. 4. velj

    Smarter solid dosage technologies cost more money, but isn’t there a better balance to be struck for the benefit of patient compliance?

    Poništi
  7. 3. velj

    BASF has launched three virtual assistants for improved efficiency and effectiveness in offering customers access to real-time information and the opportunity to better navigate the regulatory landscape. Watch the full interview with David Friedinger 👇

    Poništi
  8. 2. velj

    Alessandra Vizza, Regional Business Director talks about the benefits of these tools – and how she expects them to evolve in the coming years.

    Poništi
  9. 31. sij

    Over 2 billion people worldwide don’t have sufficient access to essential medicines and health products. Many are frustrated because of the failure to help patients in meaningful ways. So how do we move forward?

    Poništi
  10. 31. sij

    Flore Laporte Fauret describes how One Vision, SGS' lab digitalization initiative is standardizing record-keeping procedures and maintaining excellence across its global network. Watch the full video below 👇

    Poništi
  11. 28. sij

    Gen Li and Jonathan Peachey both at Phesi, explain the importance of predictive analytical tools for companies struggling to keep up with ever-growing sources of data. Click below to read more:

    Poništi
  12. 28. sij

    When poor medical adherence contributes to 200,000 deaths each year, what can be done to lessen the problem? Click below to read the full article:

    Poništi
  13. 27. sij

    Christian Jones from explains the opportunities for using new technologies, like nanotechnology, to reduce drug development efficiency and better medicines for patients. Watch the full video on our YouTube channel 👇

    Poništi
  14. 27. sij

    Is US pharma ready for another recession? George Chressanthis gives his view here:

    Poništi
  15. 27. sij

    With “no-deal” very much still on the table in the UK’s Brexit negotiations, find out how Merck is mitigating the risks in this interview with Frithjof Holtz. Click below to read more:

    Poništi
  16. 27. sij

    We spoke to Nathan Wineinger, Director of Biostatistics and Assistant Professor at Scripps Research about the state of the US' drug market and the reforms that could be made to help the US citizens. Click below to read more:

    Poništi
  17. 26. sij

    When seeking innovation, first and foremost we are looking for patient benefit.” Andrew Davies and Nigel Blackburn discuss the importance of patient-centricity for drug development.

    Poništi
  18. 26. sij

    It is essential that the quality of analytical methods be assured all the way from development and validation to routine use and transfer. Click below to read more:

    Poništi
  19. 26. sij

    In May 2019, GE Healthcare brought experts together at its Uppsala, Sweden, site for Bioprocess Days: an event to discuss the future of bioprocessing. Click below to read more:

    Poništi
  20. 25. sij

    Should pharma companies transition from developing, manufacturing and pricing “drugs” to promoting “health”? Click below to read the full article:

    Poništi
  21. 25. sij

    Inmune Bio CEO, RJ Tesi, wants to also bring the innate immune system to the fight. We asked him more about the company’s research. Click below to read more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·